Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Wants Japan, U.S. To Work Out Prevacid Taxing

This article was originally published in PharmAsia News

Executive Summary

Takeda Pharmaceutical is urging the Japanese and U.S. governments to determine which country alone will tax sales of its Prevacid (lansoprazole) ulcer drug. The drug maker already is involved in a 2006 dispute with competing taxing authorities in the two countries over the drug, which Takeda marketed at the time with TAP Pharmaceuticals of the United States. A Takeda subsidiary later absorbed TAP. Takeda's request involves all cross-border product transactions Takeda makes in the two countries. (Click here for more - a subscription may be required

You may also be interested in...



Japanese Tax Authorities Eye New Pharma Targets; Takeda Seeks To Resolve Double Taxation On Prevacid

TOKYO - Japanese tax authorities increasingly are looking at management costs during transfer-pricing investigations of pharmaceutical companies, shifting away from a focus on overseas R&D costs

Recent And Upcoming FDA Advisory Committee Meetings

Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.

What To Consider For German Orphan Drug Price Negotiations

The German pricing and reimbursement system has been successful in recognizing the value and uniqueness of orphan drugs.

UsernamePublicRestriction

Register

LL1134940

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel